Vanguard Group Inc Sells 6,723 Shares of Cue Biopharma Inc (CUE)
Vanguard Group Inc cut its stake in Cue Biopharma Inc (NASDAQ:CUE) by 1.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 661,616 shares of the company’s stock after selling 6,723 shares during the quarter. Vanguard Group Inc’s holdings in Cue Biopharma were worth $5,987,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in CUE. Sphera Funds Management LTD. purchased a new stake in shares of Cue Biopharma during the third quarter worth approximately $181,000. Schwab Charles Investment Management Inc. grew its holdings in shares of Cue Biopharma by 103.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,100 shares of the company’s stock worth $393,000 after purchasing an additional 16,800 shares during the period. Bank of New York Mellon Corp lifted its stake in Cue Biopharma by 99.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 44,505 shares of the company’s stock worth $527,000 after acquiring an additional 22,229 shares in the last quarter. P.A.W. Capital Corp lifted its stake in Cue Biopharma by 166.7% during the 3rd quarter. P.A.W. Capital Corp now owns 80,000 shares of the company’s stock worth $724,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Cue Biopharma by 140.2% during the 2nd quarter. Northern Trust Corp now owns 180,486 shares of the company’s stock worth $2,141,000 after acquiring an additional 105,333 shares in the last quarter. 17.30% of the stock is owned by institutional investors.
Shares of NASDAQ CUE traded down $0.03 during midday trading on Monday, hitting $5.40. 805 shares of the company’s stock were exchanged, compared to its average volume of 55,389. Cue Biopharma Inc has a twelve month low of $4.16 and a twelve month high of $17.99.
In other Cue Biopharma news, Director Christopher A. Marlett acquired 7,543 shares of the stock in a transaction dated Tuesday, December 11th. The stock was acquired at an average price of $4.86 per share, with a total value of $36,658.98. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher A. Marlett acquired 10,000 shares of the stock in a transaction dated Thursday, December 13th. The stock was acquired at an average cost of $5.06 per share, with a total value of $50,600.00. The disclosure for this purchase can be found here. Insiders bought a total of 85,111 shares of company stock valued at $400,262 over the last three months. Insiders own 18.60% of the company’s stock.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers and autoimmune disorders. The company's lead drug candidate includes CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to human papilloma virus related cancers.
Featured Article: Are all No-Load Funds Equal?
Want to see what other hedge funds are holding CUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cue Biopharma Inc (NASDAQ:CUE).
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.